Immune changes in muscle-invasive bladder cancer after pre-surgery treatment
Part of Cancer, Immune system & allergy, Kidney & urinary clinical trials.
This study looks at how chemotherapy given before bladder removal surgery changes the immune environment around the tumor. The goal is to see if these changes can help predict how well the treatment works, which could lead to better personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with muscle-invasive bladder cancer that has not spread to distant organs (like the lungs or liver).
- Your doctor has decided that you are well enough to have surgery to remove your bladder (radical cystectomy).
- You are generally in good health, with an ECOG performance status of 0–2, meaning you can do most daily activities on your own.
- You have not had another cancer in the last 5 years (unless it was cured and you are not currently on treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This study tests a new immunotherapy drug called sasanlimab as a maintenance treatment after chemotherapy and bladder removal surgery. The goal is to see if it helps keep the cancer from coming back in people with muscle-invasive bladder cancer.
This trial compares three standard treatments for muscle-invasive bladder cancer: bladder removal surgery, radiation combined with chemotherapy, or both. It aims to find which approach works best while preserving quality of life.
This trial tests giving chemotherapy before surgery to remove the bladder, to see if it can improve outcomes for patients with muscle-invasive bladder cancer. The treatment is personalized based on a lab test of your tumor cells, which may help make the therapy more effective.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.